SCHEMBL4099544

SCHEMBL4099544

CCOC(=O)c1cnc(S(C)(=O)=O)nc1NC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
ALDH1A1 P00352 3/20 0.56
NPC1 O15118 2/20 0.56
HSD17B10 Q99714 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
TP53 P04637 1/20 0.56
XBP1 P17861 1/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
TLR9 Q9NR96 1/20 0.56
KDM4E B2RXH2 4/20 0.54
HPGD P15428 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.47
FOS P01100 5/20 0.47
JUN P05412 5/20 0.47
NFKB1 P19838 5/20 0.47
NFKB2 Q00653 5/20 0.47
RELA Q04206 5/20 0.47
RECQL P46063 1/20 0.43
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763594 0.84 MAPT (0.63) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL15624862 0.81 ALDH1A1 (0.60) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL1901370 0.81 MAPT (0.59) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL31148371 0.81 MAPT (0.59) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL1628005 0.81 MAPT (0.67) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL14800642 0.80 ALDH1A1 (0.58) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL14810384 0.79 KDM4E (0.57) MAPTALDH1A1NPC1HSD17B10KDM4E
SCHEMBL541532 0.78 ALDH1A1 (0.56) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL12795952 0.77 ALDH1A1 (0.55) MAPTALDH1A1NPC1HSD17B10NPSR1
SCHEMBL14590421 0.77 ALDH1A1 (0.57) MAPTALDH1A1NPC1HSD17B10NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 MAPT 1964/4885ALDH1A1 635/4885NPC1 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.